Holen Sie sich die Stockscreener-App
1.42
1.43%
0.02
Handel nachbörslich:
1.40
-0.02
-1.41%
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - GlobeNewswire
Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan
Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq
Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire
New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial - Investing.com
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - marketscreener.com
3 Reasons to Avoid HEES and 1 Stock to Buy Instead - The Globe and Mail
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Yahoo Finance
U.S. Exosomes Market to Surge from $101 Million to $1,917.72 Million by 2034 | Towards Healthcare - Yahoo Finance
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo Finance
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Yahoo Finance
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - Yahoo Finance
If You Invested $10K In PotlatchDeltic Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Yahoo Finance
Why Viking Holdings Ltd. (VIK) Surged On Tuesday? - Yahoo Finance
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease - Yahoo Finance
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - Yahoo Finance
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - Yahoo Finance
Zevra Therapeutics Files Preliminary Proxy - Yahoo Finance
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference - The Manila Times
Pasithea Therapeutics to Present at 2025 CAGLA NeauxCancer Conference on Next-Generation MEK Inhibitor PAS-004 - Nasdaq
New Clinical Data: Pasithea's Novel Cancer Drug Shows Promise in Phase 1 Trial - Stock Titan
Down 42%, Should You Buy Tesla Stock on the Dip? - The Globe and Mail
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer - Yahoo Finance
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - Yahoo Finance
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer - Yahoo Finance
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Yahoo Finance
KTTA stock touches 52-week low at $1.12 amid market challenges - Investing.com India
KTTA stock touches 52-week low at $1.12 amid market challenges By Investing.com - Investing.com South Africa
Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
AvePoint Announces Fourth Quarter and Full Year 2024 Financial Results - The Globe and Mail
Super Micro stock rallies after meeting Nasdaq deadline to avoid delisting - Yahoo Finance
KTTA stock touches 52-week low at $1.24 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Pasithea's PAS-004 advances in cancer trial with no toxicities - MSN
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... - Yahoo Finance
AvePointHas An A-Client List - The Globe and Mail
KTTA stock touches 52-week low at $1.32 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update - Defense World
Pasithea Therapeutics Corp (KTTA) Stock: A Study of the Market Performance - The News Heater
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):